Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
CellSight Technologies General Information
CellSight Technologies has developed [18F]F-AraG (VisAcT), a PET imaging agent that preferentially accumulates in activated T cells, enabling their tracking throughout the body. Recent studies have shown its ability to predict survival in immunotherapy-treated non-small cell lung cancer patients and reveal long-term immune system activation following COVID-19 infection.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
San Francisco, California
United States
United States
Drug Pipeline
[18F]F-AraG
Phase 2Key Partnerships
UCSF, UC Davis, Dana Farber, Stanford University, Kyoto University
CellSight Technologies Funding
No funding data available
To view CellSight Technologies's complete valuation and funding history, request access »